All Products

Oncomine Tumor Mutation Load Assay

Detection of cancer driver variants and assessment of tumor mutational burden (TMB), an emerging immuno-oncology biomarker, with next-generation sequencing immune checkpoint inhibitors have changed the treatment paradigm for a variety of cancers, but not all patients will respond to immunotherapies. Relevant biomarkers have shown to be as important as the therapies since they guide in our quest to help match patients with the appropriate treatment.
Our multi-biomarker next-generation sequencing (NGS)-based assays have been adopted by leading cancer institutions to comprehensively profile thousands of clinical research samples (one example is the NCI-Match Trial Assay). Given the complexity of the immune response and tumor biology, additional biomarkers are needed to evaluate their associations with response to immuno-oncology (I-O) therapies. Tumor mutational burden (TMB) is an exciting biomarker in multiple disease types that may further immunotherapy research.
The Ion Torrent Oncomine Tumor Mutation Load Assay is a robust, targeted next-generation sequencing (NGS) assay designed for tumor profiling by annotation of cancer driver variants and provides accurate quantification of TMB from limited formalin- fixed, paraffin-embedded (FFPE) samples. Our streamlined, built-in analysis solution allows you to confidently detect cancer driver variants and assess tumor mutational burden in ~2.5 days for your research studies.